Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing 100853, China
Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang JE, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012; 379(9818): 815–822
[2]
Wang J, Zhang L, Wang F, Liu L, Wang H; the China National Survey of Chronic Kidney Disease Working Group. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens 2014; 27(11): 1355–1361
[3]
Zheng Y, Cai GY, Chen XM, Fu P, Chen JH, Ding XQ, Yu XQ, Lin HL, Liu J, Xie RJ, Wang LN, Ni ZH, Liu FY, Yin AP, Xing CY, Wang L, Shi W, Liu JS, He YN, Ding GH, Li WG, Wu GL, Miao LN, Chen N, Su Z, Mei CL, Zhao JY, Gu Y, Bai YK, Luo HM, Lin S, Chen MH, Gong L, Yang YB, Yang XP, Li Y, Wan JX, Wang NS, Li HY, Xi CS, Hao L, Xu Y, Fang JA, Liu BC, Li RS, Wang R, Zhang JH, Wang JQ, Lou TQ, Shao FM, Mei F, Liu ZH, Yuan WJ, Sun SR, Zhang L, Zhou CH, Chen QK, Jia SL, Gong ZF, Guan GJ, Xia T, Zhong LB; Prevalence, Awareness, and Treatment Rates in Chronic Kidney Disease Patients with Hypertension in China (PATRIOTIC) Collaborative Group. Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients. Chin Med J (Engl) 2013; 126(12): 2276–2280
[4]
Zhang W, Shi W, Liu Z, Gu Y, Chen Q, Yuan W, Zhang Y, Gong L, Zhou R, Li M, Cheng H, Liu J, Cen J, Huang C, Ren Y, Mao P, Xing C, Hong F, Jiang D, Wang L, Xu G, Liu J, Chen N. A nationwide cross-sectional survey on prevalence, management and pharmacoepidemiology patterns on hypertension in Chinese patients with chronic kidney disease. Sci Rep 2016; 6(1): 38768
[5]
Wang C, Deng WJ, Gong WY, Zhang J, Tang H, Peng H, Zhang QZ, Ye ZC, Lou T. High prevalence of isolated nocturnal hypertension in Chinese patients with chronic kidney disease. J Am Heart Assoc 2015; 4(6): e002025
[6]
Cai G, Zheng Y, Sun X, Chen X; Survey of Prevalence, Awareness, and Treatment Rates in Chronic Kidney Disease Patients with Hypertension in China Collaborative Group. Prevalence, awareness, treatment, and control of hypertension in elderly adults with chronic kidney disease: results from the survey of Prevalence, Awareness, and Treatment Rates in Chronic Kidney Disease Patients with Hypertension in China. J Am Geriatr Soc 2013; 61(12): 2160–2167
[7]
Wang Y, Zhang L, Li X, Xu Y, Yang M, Qian J, Wang L, Chen N, Gu Y, Chen M, Xing C, Chen X, Hou F, Yu X, Cheng X, Guo L, Wei C, Huang G, Zhang Q, Wang R, Wang L, Mei C, Li Y, Liu Z, Zhao L, Wu Y, Wang HY. Improvement of awareness, treatment and control of hypertension among chronic kidney disease patients in China from 1999 to 2005. Hypertens Res 2009; 32(6): 444–449
[8]
Chow KM, Szeto CC, Kwan B, Leung CB, Li PK. Public lacks knowledge on chronic kidney disease: telephone survey. Hong Kong Med J 2014; 20(2): 139–144
[9]
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group.KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl2012;2:337‒414
[10]
Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(5 Suppl 1): S1–S290
[11]
Wang C, Zhang J, Liu X, Li CC, Ye ZC, Peng H, Chen Z, Lou T. Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern. J Clin Hypertens (Greenwich) 2013; 15(1): 48–54
[12]
Wang C, Qiu X, Lv L, Huang J, Li S, Lou T, Liu X. Chronotherapy for hypertension in patients with chronic kidney disease: a systematic review and meta-analysis in non-black patients. Int Urol Nephrol 2017; 49(4): 651–659
[13]
Zhou YL, Liu J, Ma LJ, Sun F, Shen Y, Huang J, Cui TG. Effects of increasing diffusive sodium removal on blood pressure control in hemodialysis patients with optimal dry weight. Blood Purif 2013; 35(1-3): 209–215
[14]
Zhang X, Feldmam R, Wu Z, Zhang Y, Yu X, Liu L. Therapeutic inertia is a major determinant if BP control rates in China. A hypertension attitude perspectives and needs (HAPPEN) study report. J Hypertens 2015; 33(Suppl 1):e128
[15]
Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J, Deo R, Fischer MJ, He J, Hsu CY, Huan Y, Keane MG, Kusek JW, Makos GK, Miller ER 3rd, Soliman EZ, Steigerwalt SP, Taliercio JJ, Townsend RR, Weir MR, Wright JT Jr, Xie D, Rahman M; Chronic Renal Insufficiency Cohort Study Investigators. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage. Clin J Am Soc Nephrol 2016; 11(4): 642–652
[16]
Wang C, Li Y, Zhang J, Ye ZC, Zhang QZ, Ma XX, Peng H, Lou TQ. Prognostic effect of isolated nocturnal hypertension in Chinese patients with nondialysis chronic kidney disease. J Am Heart Assoc 2016; 5(10): e004198
[17]
Minutolo R, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, Nappi F, Stanzione G, Conte G, De Nicola L. Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study. Am J Kidney Dis 2014; 64(5): 744–752
RIGHTS & PERMISSIONS
Higher Education Press and Springer-Verlag Berlin Heidelberg